Table 3.
Associations between patients and treatment characteristics and cognitive disturbance
| Covariate | Cognitive disturbance N (%) |
No cognitive disturbance N (%) |
Odds ratio (95% CI) |
p-value |
|---|---|---|---|---|
| Protocol | 0.001 | |||
| 58741 | 19 (65.5) | 10 (34.5) | 1 | |
| 58831/2 | 18 (16.2) | 93 (83.8) | 0.10 (0.04–0.26) | |
| 58881 | 68 (15.3) | 376 (84.7) | 0.09 (0.04–0.21) | |
| Age at diagnosis, years | 0.510* | |||
| < 6 | 75 (18.8) | 323 (81.2) | 1 | |
| 6–9 | 19 (17.9) | 87 (82.1) | 0.90 (0.50–1.62)* | |
| 10–17 | 11 (13.8) | 69 (86.3) | 0.66 (0.32–1.34)* | |
| CNS involvement at diagnosis | 0.536* | |||
| No CNS involvement | 98 (17.8) | 452 (82.2) | 1 | |
| CNS involvement | 6 (21.4) | 22 (78.6) | 1.36 (0.52–3.55)* | |
| HSCT | 0.233* | |||
| No | 94 (17.7) | 438 (82.3) | 1 | |
| Yes | 11 (21.2) | 41 (78.8) | 1.54 (0.76–3.14)* | |
| VHR after consolidation** | 0.682 | |||
| Not VHR | 63 (15.7) | 339 (84.3) | 1 | |
| VHR | 4 (12.9) | 27 (87.1) | 0.80 (0.27–2.36) | |
| Randomized HD Cytarabine** | 0.861 | |||
| No HD Cytarabine | 15 (20.0) | 60 (80.0) | 1 | |
| HD Cytarabine | 13 (18.8) | 56 (81.2) | 0.93 (0.41–2.12) | |
CNS, central nervous system; HD Cytarabine, high-dose cytarabine; HSCT, hematopoietic stem cell transplantation; VHR, very high risk.
*Adjusted for protocol
**Based on the 58881 study only